Reviewing the Rationale for Cross-Shareholdings and the Reduction Policy
First written in FY2020. 1 of 3 entries say "Advanced", first in FY2022. Latest entry: FY2025.
- FY2025RestatedAnnual report
「The Company verifies the significance of holding each individual cross-shareholding every fiscal year. At a meeting of the Board of Directors held on 7 February 2025, it verified the rationale for continuing to hold the cross-shareholdings currently held.」
The Company continues to review each individual cross-shareholding and confirm the rationale for holding it every fiscal year. During the fiscal year, the review was conducted at a meeting of the Board of Directors held on 7 February 2025. - FY2022AdvancedAnnual report
「Following a review of the quantitative benefits of the holdings, 45,000 shares were sold during the fiscal year.」
Following a review of the rationale for cross-shareholdings, 45,000 shares of 大木ヘルスケアホールディングス were sold. - FY2020First statedAnnual report
「For shares held, the Board of Directors verifies each year, for each individual issue, dividend income and economic rationale, as well as the significance and appropriateness of continued ownership, including maintaining and strengthening business relationships, and establishes and reviews policies for reducing or selling the holdings.」
For cross-shareholdings, the Company has for the first time expressly stated as an independent policy its annual review of individual holdings, confirmation of their significance and economic rationale, and policy on reducing or selling them.